CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The HAP2 project focuses on creating targeted drugs and biomarkers to improve the prevention and treatment of hospital-acquired pneumonia. By understanding host-pathogen interactions and immune responses, it aims to enhance patient outcomes in this serious infectious disease.
“HAP2” aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of hospital-acquired pneumonia (HAP) and develop precision medicine in infectious diseases. HAP is an infectious disease of major concern in the world, and the most frequent cause of hospital-acquired infections with 500,000 episodes being treated every year in Europe.
Despite the development of European recommendations, the incidence remains high, with dramatic medical consequences:…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Nantes
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, Barcelona
Type: Research institute
Activity type: Research Organisations
SME: No
Switzerland, Zurich
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
